服用礼来Orforglipron的患者平均减轻16磅,相当于体重的7.9%。相比之下,诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 4月17日,礼来盘初涨超16%,公司的口服减肥药Orforglipron在三期临床试验中表现出色,有望成为无需注射的减肥药替代品。试验结果显示,礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.